People

Nanna Lüneborg

MapLight Therapeutics director and Forbion general partner focusing on clinical-stage biotechnology. Previously invested at Novo Holdings and Apposite Capital. Holds a UCL neuroscience doctorate, a Cambridge MBA and an Oxford undergraduate degree.